Not investment advice. FilingSight is an automated analytical research tool, not a registered investment advisor. Ratings and scores are quantitative analytical classifications, not buy or sell recommendations. Nothing here is personalized to your circumstances. Investing involves risk of loss — consult a licensed professional. See full disclosures.
Create a free account to read 3 full reports each month — plus a 14-day Pro trial. Get started →
Amgen Inc.
AMGNHealthcareGenerated Jul 5, 2026, 08:54 PM UTC
AMGN (Amgen Inc.) analytical snapshot. Return on equity 183.47%, ROA 7.31%, ROIC 12.39%. Net income up ▲ +2.5% YoY. Debt/equity 6.24, current ratio 1.26, net debt $45.28B. Market cap $201.93B at $374.15 per share. Trailing P/E 29.96, P/S 8.50, P/B 21.97. EV/Operating income ≈ 31.31 (EV $247.22B). Risk: Moderate. Macro: Risk-on · Supportive. Composite analytical score -14 (data confidence 82%). Descriptive analytics from public filings — not investment advice.
Market cap
$201.93B
539.71M shares
Price
$374.15
NMS
P/E (ttm)
29.96
Revenue (FY)
—
Net margin
—
Free cash flow
$7.36B
Risk level
Moderate
Free SEC analysis
— computed from SEC filings, free to readFree previewFundamentals Analyst
Fundamentals
Fundamentals Analyst
score -5Stable
80% conf
Return on equity 183.47%, ROA 7.31%, ROIC 12.39%. Net income up ▲ +2.5% YoY. Debt/equity 6.24, current ratio 1.26, net debt $45.28B.
- Return on equity 183.47%, ROA 7.31%, ROIC 12.39%.
- Net income up ▲ +2.5% YoY.
- Debt/equity 6.24, current ratio 1.26, net debt $45.28B.
Revenue (FY)
—
Net margin
—
ROE
183.47%
ROA 7.31%
ROIC
12.39%
EPS (diluted)
$12.49
FY2025
Free cash flow
$7.36B
Debt / equity
6.24
Cash $12.04B
Current ratio
1.26
Equity $9.19B
Annual fundamentals — up to 10 years (SEC 10-K, US-GAAP)
| FY | Revenue | Rev YoY | Gross% | Op% | Net% | FCF | ROE% |
|---|---|---|---|---|---|---|---|
| 2016 | $20.06B | — | 19.14 | 30.86 | 25.71 | $8.23B | 23.34 |
| 2017 | $21.66B | +8.0% | 19.49 | 39.10 | 32.03 | $9.14B | 26.92 |
| 2018 | $22.99B | +6.1% | 18.28 | 42.60 | 33.59 | $9.62B | 27.50 |
| 2019 | $22.85B | -0.6% | 19.25 | 43.65 | 8.66 | $10.51B | 6.62 |
| 2020 | $23.75B | +3.9% | 17.82 | 43.22 | 35.35 | $10.56B | 33.26 |
| 2021 | — | — | — | — | — | $8.53B | 62.74 |
| 2022 | — | — | — | — | — | $9.89B | 75.10 |
| 2023 | — | — | — | — | — | $8.38B | 62.63 |
| 2024 | — | — | — | — | — | $8.79B | 97.79 |
| 2025 | — | — | — | — | — | $7.36B | 183.47 |
Quarterly revenue trend (last 6 quarters, SEC 10-Q)
| Quarter end | Revenue | YoY | QoQ | Net margin |
|---|---|---|---|---|
| Jun 30, 2020 | $6.21B | -45.7% | — | 58.46% |
| Sep 30, 2020 | $18.79B | +9.5% | +202.8% | 30.06% |
| Sep 30, 2020 | $6.42B | -62.6% | -65.8% | 87.95% |
| Mar 31, 2021 | $5.90B | -4.2% | -8.1% | 27.89% |
| Jun 30, 2021 | $12.43B | +0.5% | +110.6% | 16.98% |
| Jun 30, 2021 | $6.53B | -47.2% | -47.5% | 32.33% |
Revenue (annual, SEC 10-K)
2016: 20,063
2017: 21,662
2018: 22,991
2019: 22,849
2020: 23,747
2021: 0
2022: 0
2023: 0
2024: 0
2025: 0
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Profitability trends (%)
GrossOperatingNet
Free cash flow (annual)
2016: 8,234
2017: 9,137
2018: 9,616
2019: 10,513
2020: 10,558
2021: 8,532
2022: 9,889
2023: 8,381
2024: 8,785
2025: 7,359
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sources:SEC EDGAR — Company Facts (XBRL)
Free previewRegulatory Analyst
Filings & Ownership
Regulatory Analyst
score 30Improving
80% conf
Latest annual report (10-K) filed Feb 13, 2026. Latest quarterly report (10-Q) filed May 1, 2026. 9 recent 8-K material-event filings in the index.
- Latest annual report (10-K) filed Feb 13, 2026.
- Latest quarterly report (10-Q) filed May 1, 2026.
- 9 recent 8-K material-event filings in the index.
- Recent insider Form 4s: 0 buy vs 0 sell transactions.
- ~10,000+ recent 13F-HR filings reference Amgen Inc.; broad institutional reporting.
- Recent filers include THURSTON, SPRINGER, MILLER, HERD & TITAK, INC., Visium Asset Management LLC, LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA.
- 12 recent 13D activist/beneficial-ownership filings — potential catalyst.
- 8 recent 13G passive institutional ownership notices.
Latest 10-K
Feb 13, 2026
Annual report
Latest 10-Q
May 1, 2026
8-K (recent)
9
Insider net
—
0B/0S
13F filers
10k+
Activist 13D
12
Recent 13F institutional filers (SEC EDGAR full-text)
| Filer | Form | Filed |
|---|---|---|
| THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. | 13F-HR | May 14, 2024 |
| Visium Asset Management LLC | 13F-HR | May 15, 2007 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | Feb 12, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 11, 2004 |
| LORING WOLCOTT & COOLIDGE FIDUCIARY ADVISORS /MA | 13F-HR | May 15, 2003 |
Recent 8-K material events
| Date | Form | Description |
|---|---|---|
| May 20, 2026 | 8-K | 8-K |
| May 19, 2026 | 8-K | 8-K |
| Apr 30, 2026 | 8-K | 8-K |
| Apr 22, 2026 | 8-K | 8-K |
| Feb 19, 2026 | 8-K | 8-K |
| Feb 3, 2026 | 8-K | 8-K |
| Jan 30, 2026 | 8-K | 8-K |
| Nov 4, 2025 | 8-K | 8-K |
Free previewSEC Filing Analyst
SEC Filing Deep-Analysis
SEC Filing Analyst
score -61Deteriorating
68% conf
4 risk signal(s), 1 positive signal(s), 1 watch item(s) detected from XBRL filing diff analysis. 4 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- Interest coverage deteriorating below 3x: Interest coverage fell from 6.80x to 2.75x. Operating income of $7.90B covers interest of $2.88B only 2.75x — approaching the threshold where debt service becomes constrained. Monitor for covenant breaches.
- NEW: Going concern doubt in latest filing: The term "going concern" appears in recent 10-K/10-Q filings but was NOT present in the prior 24-month period. This is a new risk disclosure that warrants attention. Found in 4 filing(s).
- Material weakness in internal controls: The term "material weakness" appears in 19 recent filing(s) (vs 2 in the prior period). This risk language is ongoing.
- Restatement of financial statements: The term "restate" "financial statements" appears in 11 recent filing(s) (vs 1 in the prior period). This risk language is ongoing.
- Operating cash flow exceeds net income: OCF is 1.26x net income, indicating high earnings quality — cash conversion is strong and accruals are not inflating reported profits.
- NEW: Off-balance sheet arrangements: Off-balance sheet arrangements appears in recent filings but not in the prior 24-month period. Monitor for materiality.
- Endogenous analysis: 4 risk signal(s) detected versus 1 positive signal(s). The balance of evidence suggests elevated filing-specific risk that warrants monitoring in subsequent filings.
- 3 new XBRL disclosure(s) in latest filing — expanding reporting scope.
- 20 disclosure(s) dropped from prior year — reduced reporting granularity.
- 2 new risk-language term(s) detected in filing text: Going concern doubt, Off-balance sheet arrangements.
- Ongoing high-severity risk language: Material weakness in internal controls, Restatement of financial statements.
Revenue
$23.75B
+3.9% YoY
Gross profit
$4.23B
-3.8% YoY
Operating income
$7.90B
-17.4% YoY
Net income
$6.72B
+2.5% YoY
Operating cash flow
$8.47B
-12.9% YoY
Capex
$1.11B
+18.8% YoY
Total assets
$91.84B
-5.5% YoY
Long-term debt
$60.10B
-7.0% YoY
Filing quality score
76/100
3 new disclosures
SEC XBRL metric changes (latest annual vs prior)
| Metric | Prior year | Latest year | Change | % Change |
|---|---|---|---|---|
| Revenue | $22.85B | $23.75B | $898.0M | +3.9% |
| Gross profit | $4.40B | $4.23B | $-168.0M | -3.8% |
| Operating income | $9.57B | $7.90B | $-1.67B | -17.4% |
| Net income | $6.55B | $6.72B | $165.0M | +2.5% |
| Operating cash flow | $9.72B | $8.47B | $-1.25B | -12.9% |
| Capex | $936.0M | $1.11B | $176.0M | +18.8% |
| Total assets | $97.15B | $91.84B | $-5.32B | -5.5% |
| Long-term debt | $64.61B | $60.10B | $-4.51B | -7.0% |
| Cash & equivalents | $10.94B | $11.97B | $1.03B | +9.4% |
| Stockholders equity | $6.70B | $3.66B | $-3.04B | -45.4% |
| Inventory | $9.52B | $7.00B | $-2.52B | -26.5% |
| Accounts receivable | $7.27B | $6.78B | $-486.0M | -6.7% |
| SG&A expense | $5.41B | $6.18B | $765.0M | +14.1% |
| Interest expense | $1.41B | $2.88B | $1.47B | +104.5% |
XBRL disclosure changes (new vs dropped concepts)
| Type | Concepts |
|---|---|
| Added | DebtInstrumentFaceAmount, LineOfCredit, OtherNonrecurringIncomeExpense |
| Removed | AccruedIncomeTaxesCurrent, AdvertisingExpense, AllocatedShareBasedCompensationExpense, BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1, CapitalizedContractCostNet, CommercialPaper, CurrentFederalTaxExpenseBenefit, CurrentForeignTaxExpenseBenefit, CurrentIncomeTaxExpenseBenefit, CurrentStateAndLocalTaxExpenseBenefit |
Risk language in filing text (EDGAR full-text search)
| Term | Severity | Recent | Prior | Status |
|---|---|---|---|---|
| Going concern doubt | high | 4 | 0 | NEW |
| Material weakness in internal controls | high | 19 | 2 | Ongoing |
| Restatement of financial statements | high | 11 | 1 | Ongoing |
| Impairment charge | medium | 35 | 5 | Ongoing |
| Restructuring | medium | 78 | 8 | Ongoing |
| Off-balance sheet arrangements | medium | 19 | 0 | NEW |
| Related party transactions | low | 47 | 1 | Ongoing |
Filing signal breakdown
Red flags: 4
Positive: 1
Watch: 1
Red flags
Positive
Watch
Unlock the rest
- ProValuationMarket cap $201.93B at $374.15 per share.
- ProPrice & TechnicalsPrice $374.15 — uptrend (above 200-DMA); 1-month momentum positive.
- ProMacro & RatesMarket regime: Risk-on · Supportive.
- ProRisk ScorecardComposite risk: Moderate.
This content is for Pro subscribers
Unlock the full breakdown from all analysts — valuation (DCF & Graham), price & technicals, macro, risk scorecard, and 13F/13D ownership flow — plus your research workspace.
3 sections free · 4 Pro sections locked · composite -14
Macro exposure
Defensive · Low sensitivityMacro regime: Risk-on · Supportive. Amgen Inc. is a defensive name (low macro sensitivity) — a supportive backdrop, though defensives lag risk-on tapes.
Macro regime
Risk-on · Supportive
Yield curve
Normal
VIX
16.59
Fed funds
3.63%
CPI YoY
+4.2%
Analytical read
deterministic previewPrice $374.15 — uptrend (above 200-DMA); 1-month momentum positive..
Risk
Moderate
Macro regime
Risk-on · Supportive
Macro exposure
Neutral
Descriptive analytics from public filings and macro data — not investment advice.
Peer comparison
Defensive groupHow AMGN stacks up against tracked peers with similar macro sensitivity — by analytical score and macro exposure.
| Company | Score | Macro |
|---|---|---|
| Bristol-Myers Squibb BMY | 12 | Neutral |
| Cigna Group CI | 9 | Neutral |
| Procter & Gamble PG | 9 | Neutral |
| UnitedHealth Group UNH | 6 | Neutral |
| CVS Health Corp. CVS | 6 | Neutral |
| Zoetis Inc. ZTS | 3 | Neutral |
| Eli Lilly & Co. LLY | 3 | Neutral |
| Colgate-Palmolive CL | 1 | Neutral |
| Coca-Cola Co. KO | 1 | Neutral |
| Gilead Sciences GILD | 1 | Neutral |
| Intuitive Surgical Inc. ISRG | -1 | Neutral |
| Moderna Inc. MRNA | -4 | Neutral |
| Regeneron Pharmaceuticals REGN | -4 | Neutral |
| DexCom Inc. DXCM | -7 | Neutral |
| AbbVie Inc. ABBV | -7 | Neutral |
| Johnson & Johnson JNJ | -7 | Neutral |
| Vertex Pharmaceuticals VRTX | -8 | Neutral |
| Kimberly-Clark Corp. KMB | -10 | Neutral |
| Sysco Corp. SYY | -10 | Neutral |
| Danaher Corp. DHR | -11 | Neutral |
| Mondelez International MDLZ | -11 | Neutral |
| Merck & Co. MRK | -11 | Neutral |
| Biogen Inc. BIIB | -11 | Neutral |
| Amgen Inc. AMGN● you | -14 | Neutral |
| HCA Healthcare HCA | -14 | Neutral |
| Illumina Inc. ILMN | -16 | Neutral |
| Kroger Co. KR | -16 | Neutral |
| Thermo Fisher Scientific TMO | -18 | Neutral |
| Costco Wholesale COST | -18 | Neutral |
| PepsiCo Inc. PEP | -21 | Neutral |
| Walmart Inc. WMT | -25 | Neutral |
| Hershey Co. HSY | -26 | Neutral |
| Abbott Laboratories ABT | -30 | Neutral |
| Pfizer Inc. PFE | -49 | Neutral |